NCT04926623

Brief Summary

Multicenter, Open-label, Randomized Trial to Compare the Effectiveness of Structured Education and Safety of FreeStyle Libre or Self-Monitoring of Blood Glucose (SMBG) in patients with type 2 Diabetes Mellitus using Multiple Daily Injections or Insulin Pumps

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
159

participants targeted

Target at P75+ for not_applicable type-2-diabetes-mellitus

Timeline
Completed

Started Jun 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 10, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 15, 2021

Completed
2 days until next milestone

Study Start

First participant enrolled

June 17, 2021

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 26, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 4, 2023

Completed
Last Updated

June 14, 2024

Status Verified

June 1, 2024

Enrollment Period

1.4 years

First QC Date

June 10, 2021

Last Update Submit

June 13, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • HbA1c (%) changes

    HbA1c (%) changes at 24 weeks compared to baseline

    24 weeks

Secondary Outcomes (10)

  • HbA1c (%) changes

    12 weeks

  • Percentage of time in level 2 hypoglycemia (<54 mg/dL)

    24 weeks

  • Percentage of time in level 1 hypoglycemia (<70- 54 mg/dL)

    24 weeks

  • Percentage of time in level 1 hypoglycemia (> 180 mg/dL)

    24 weeks

  • Percentage of time in level 2 hypoglycemia (> 250 mg/dL)

    24 weeks

  • +5 more secondary outcomes

Study Arms (3)

CGM with Structured Education

EXPERIMENTAL

CGM with Structured Education

Device: FreeStyle Libre 24 weeks

CGM with Standard Education

ACTIVE COMPARATOR

CGM with Standard Education

Device: FreeStyle Libre 24 weeks

SMBG with Standard Education

ACTIVE COMPARATOR

SMBG and CGM with Standard Education

Other: SMBG (22 weeks) and blind CGM (2 weeks)

Interventions

FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)

CGM with Standard EducationCGM with Structured Education

Self-Monitoring of Blood Glucose and Continuous Glucose Monitoring

SMBG with Standard Education

Eligibility Criteria

Age19 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetes patients aged 19 and under 75 years.
  • Multiple insulin injections at the time of screening (at least one base insulin and two or more fast-acting insulin. However, one insulin aspart/insulin degludec + one insulin aspart or two or more insulin aspart/insulin degludec can be included.) or those who have been using an insulin pump for at least 12 weeks.
  • HbA1c of not less than 7.5% and not more than 12.0% at the time of screening
  • patients who agree to use FreeStyle Libre for medical care and research
  • patients who voluntarily signed a written consent form

You may not qualify if:

  • Those who have difficulty in education due to severe systemic diseases (e.g., terminal renal failure requiring dialysis, cirrhosis above Child-Pugh Class C), cognitive impairment, and mental illness.
  • Those who are taking drugs that may affect metabolism per screening time (e.g., adrenocortical hormones, immunosuppressants, etc.) (However, those who have taken the same dose for more than 12 weeks until screening time and who are not scheduled to change drug dose can participate in this study.)
  • Those with clinically significant cardiovascular diseases (heart failure, angina, myocardial infarction, cerebral infarction, etc.) within 24 weeks of screening.
  • Those who have a glomerular filtration rate (eGFR) of \<15 mL/min.
  • A person with severe diabetes complications that deteriorate or newly occur within 3 months of screening and require emergency treatment.
  • Pregnant or lactating persons.
  • Pregnancy is planned during the study period, effective contraception (if condoms, oral contraceptives, intrauterine contraceptives, injections, transplants, contraceptives, or absolute abstinence, such as periodic abstinence (e.g., Krenda, ovulation, symptom body temperature) and resection are not considered as recognized contraceptives) for women or men.
  • Those who find other researchers inappropriate for participation in research.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, 135-710, South Korea

Location

Related Publications (1)

  • Kim JY, Jin SM, Sim KH, Kim BY, Cho JH, Moon JS, Lim S, Kang ES, Park CY, Kim SG, Kim JH. Continuous glucose monitoring with structured education in adults with type 2 diabetes managed by multiple daily insulin injections: a multicentre randomised controlled trial. Diabetologia. 2024 Jul;67(7):1223-1234. doi: 10.1007/s00125-024-06152-1. Epub 2024 Apr 19.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 10, 2021

First Posted

June 15, 2021

Study Start

June 17, 2021

Primary Completion

October 26, 2022

Study Completion

April 4, 2023

Last Updated

June 14, 2024

Record last verified: 2024-06

Locations